No Data
No Data
Cowealth Medical China Co.,Ltd.'s (SHSE:603122) 31% Price Boost Is Out Of Tune With Earnings
HeFu China (603122.SH): jointly with a research institute, established the "Clinical Diagnosis and Treatment AI Assistance System".
On August 12th, Guolong News reported that Hepu China (603122.SH) stated on the interactive platform that relevant platforms such as Xinhua News Agency, Hithink RoyalFlush Information Network, and Today's Headlines have all released the company's "ACME Extreme Empowerment" program. In response to the national tiered diagnosis and treatment policy, the company has cooperated with a certain research institute to create a "clinical diagnosis and treatment AI-assisted system" to digitally and intelligently assist hospitals in high-quality development.
HeFu China (603122.SH): The cumulative combined revenue from January to July was 550 million yuan, a 14.73% decrease year-on-year.
China Harmony Wealth (603122.SH) announced that the cumulative consolidated revenue from January to July 2024 was RMB ...
From January to June, the total combined revenue of Hefu China (603122.SH) was 0.481 billion yuan, a decrease of 14.94% year-on-year.
China Fortune (603122.SH) announced that its cumulative consolidated revenue for the first half of 2024 was RMB 0.481 billion, a decrease of 14.94% year-on-year.
HeFu China (603122.SH) will distribute cash dividends for the year 2023 on June 21, with a dividend of 0.06 yuan per share.
Hefu China (603122.SH) announced that it will distribute the annual report for 2023 on June 21, 2024.
By May 2024, the cumulative consolidated revenue of Hefu China (603122.SH) decreased by 13.26% year-on-year.
On June 7th, Gelunhui reported that the company's cumulative merged revenue for January-May 2024 was RMB 406 million, a 13.26% decrease from the same period last year.
No Data